TCTMD

Elixir Medical Receives CE Mark Approval for the Breakthrough Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System

Dramatically thinner scaffold combines excellent deliverability and conformability with DESolve’s market-leading clinical benefits SUNNYVALE, Calif.--(BUSINESS WIRE)--Elixir Medical Corporation, a ...
TCTMD

Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results from the EXCELLA BD Randomized Clinical Trial

Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results from the EXCELLA BD Randomized Clinical Trial for DESyne BD(TM) Novolimus Eluting Coronary Stent with Biodegradable ...
Yahoo Finance

Elixir Medical debuts IVL system in Europe

Elixir Medical has joined the growing intravascular lithotripsy (IVL) market following the CE marking of its LithiX Hertz Contact system. The LithiX device employs focal stress contact points to ...
Yahoo Finance

Elixir Medical’s LithiX HC-IVL System Data Demonstrate Sustained Safety and Efficacy at Six Months

WASHINGTON, D.C. — Oct. X, 2024 — Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced positive six-month data from the PINNACLE I study evaluating ...
FiercePharma

Elixir Medical Receives CE Mark Approval for the DESyne® BD Novolimus Eluting Coronary Stent System With Biodegradable Polymer Coating

Elixir Medical Corporation, a developer of product platforms that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE (Conformité Européenne) Mark ...
Business Wire

Akesys Medical and Elixir Medical Announce First Human Implant of the PRAVA™ Bioresorbable Scaffold for Peripheral Vascular Disease

SUNNYVALE, Calif.--(BUSINESS WIRE)--Akesys Medical, a drug-device company focused on pioneering innovative solutions for peripheral artery disease, has announced their first clinical trial and ...
Business Wire

Elixir Medical Expands Leadership Team With Addition of Alexey Nepogodiev as Executive Vice President, Global Marketing

MILPITAS, Calif.--(BUSINESS WIRE)--Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced it has appointed Alexey (Alex) Nepogodiev as Executive Vice President ...
FiercePharma

Elixir Medical Announces First Commercial Implant Of The DESolve® Novolimus Eluting Coronary Scaffold System in Europe

SUNNYVALE, Calif.--(BUSINESS WIRE)--Marking a milestone in the evolution of fully-bioresorbable drug-eluting scaffolds for interventional cardiology, the first commercial implant of Elixir Medical's ...
Business Insider

Elixir Medical Announces Significant Late Breaking Clinical Results for DynamX® Bioadaptor Demonstrating Nearly 50% Reduction in Coronary Event Rates vs. Current PCI Standard ...

Results were presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2025 in San Francisco on October 27, 2025 DynamX® bioadaptor is the first interventional technology to ...
FierceBiotech

Elixir Medical Corporation Announced Positive First-In-Man Results from Three Drug Eluting Coronary Stent Systems

SUNNYVALE, Calif. & WASHINGTON--(BUSINESS WIRE)--October 16, 2008--Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, ...
BioWorld

Items Tagged with 'Elixir Medical Corp.'

Receipt of EU MDR CE mark may not be a magic potion, but Elixir Medical Corp. is certainly feeling a boost from the regulatory nod for its mechanical Lithix hertz contact intravascular lithotripsy ...